Casserly Ivan P, Kapadia Samir R
Director of Cardiovascular Intervention, Denver VA Medical Center, Department of Cardiology, 1055 Clermont Street, Denver, CO 80220, USA.
Expert Rev Cardiovasc Ther. 2005 Jan;3(1):143-58. doi: 10.1586/14779072.3.1.143.
We are entering a new era in the percutaneous treatment of valvular heart disease. Novel techniques and devices have given rise to the possible treatment of a range of valvular heart diseases that previously necessitated surgical therapies, including aortic stenosis, pulmonary regurgitation and mitral regurgitation. Despite the enormous potential of these percutaneous therapies, enthusiasm needs to be balanced by an understanding of the challenges that need to be overcome before such therapies can be widely embraced. This review provides a critical assessment of the status of the major developments in percutaneous valvular intervention to date, and provides the authors' perspective on the current role and future potential of these techniques.
我们正在进入经皮治疗心脏瓣膜病的新时代。新技术和设备使得一系列以前需要外科治疗的心脏瓣膜病有可能得到治疗,包括主动脉瓣狭窄、肺动脉瓣反流和二尖瓣反流。尽管这些经皮治疗具有巨大潜力,但在这些治疗方法被广泛接受之前,需要了解必须克服的挑战,以平衡热情。本综述对迄今为止经皮瓣膜介入主要进展的现状进行了批判性评估,并阐述了作者对这些技术当前作用和未来潜力的看法。